רדאר קליני AI
הניסוי הקליני NCT07412236 עבור פיברוזיס בכבד, Liver Fibrosis in Chronic Hepatitis B הוא טרם החל גיוס. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן.
מחקר אחד תואם לקריטריוני המסנן
תצוגת כרטיסים
חזרה לחיפוש

A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. שלב III 1,208 אקראי סמיות כפולה מבוקר פלסבו

טרם החל גיוס
פרטי הניסויים הקליניים זמינים בעיקר באנגלית. רדאר קליני AI יכול לעזור! לחץ על 'הסבר את המחקר' כדי לצפות ולשוחח על מידע מהמחקר בשפה המועדפת עליך.
הניסוי הקליני NCT07412236 מתוכנן לבדוק את טיפול עבור פיברוזיס בכבד, Liver Fibrosis in Chronic Hepatitis B. זהו מחקר שלב III מסוג התערבותי שנמצא במצב טרם החל גיוס. גיוס המשתתפים צפוי להתחיל ב-30 בינואר 2026, במטרה לכלול 1,208 משתתפים. המחקר ינוהל על ידי ג'ייר תרפיוטיקס וצפוי להסתיים ב-30 בדצמבר 2028. מידע זה עודכן לאחרונה באתר ClinicalTrials.gov ב-17 בפברואר 2026.
סיכום קצר
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary trea...הצג עוד
כותרת רשמית

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.

מצבים רפואיים
פיברוזיס בכבדLiver Fibrosis in Chronic Hepatitis B
מזהי מחקר נוספים
  • KDN-F351-202501
מספר NCT
NCT07412236
תחילת המחקר (בפועל)
2026-01-30
עדכון אחרון שפורסם
2026-02-17
סיום המחקר (מוערך)
2028-12-30
משתתפים (מתוכנן)
1,208
סוג המחקר
התערבותי
שלב
שלב III
סטטוס
טרם החל גיוס
מילות מפתח
LIver Fibrosis in Chronic Hepatitis B
מטרה ראשית
טיפול
הקצאת טיפול
אקראי
דגם מתערב
קבוצות מקבילות
עיוורון
מרובע
זרועות / התערבויות
קבוצת משתתפים/זרועהתערבות/טיפול
ניסיHydronidone Capsule Group (270 mg)
Treatment Group
Hydronidone (270mg)
Dosage: 30 mg/capsule, three capsules taken three times daily, resulting in a total daily therapeutic dose of 270 mg. The medication is administered orally half an hour before meals.
פלצבו להשוואהHydronidone Capsule Group (Placebo Group)
Placebo Group
Hydronidone (Placebo Group)
Dosage: three capsules taken three times daily.The medication is administered orally half an hour before meals.
מדדי תוצאה ראשיים
מדד תוצאהתיאור המדידהטווח זמן
Incidence of Clinical Endpoint Events
The clinical endpoint event is a composite event, which includes progression to complications of decompensated cirrhosis (such as ascites, esophageal and gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy, etc.), hepatocellular carcinoma, liver transplantation, and liver disease-related death/all-cause death. The time of event occurrence is determined by whichever occurs first, and the occurrence of any of these events constitutes a clinical endpoint event.
From the first dose administration to the end of the treatment period (Week 261).
מדדי תוצאה משניים
מדד תוצאהתיאור המדידהטווח זמן
Annualized Incidence Rate of Clinical Endpoint Events
From the first dose administration to the end of the treatment period (Week 261).
The incidence rates of individual components of the clinical endpoint events
From the first dose administration to the end of the treatment period (Week 261).
The annualized incidence rates of individual components of the clinical endpoint events
From the first dose administration to the end of the treatment period (Week 261).
Change from baseline in liver stiffness measurement (LSM) by transient elastography (kPa) after treatment.
From the first dose administration to the end of the treatment period (Week 261).
Undetectable rate of Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment (below the lower limit of detection).
From the first dose administration to the end of the treatment period (Week 261).
Magnitude of reduction in Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment.
From the first dose administration to the end of the treatment period (Week 261).
Magnitude of improvement in alanine aminotransferase (ALT) levels after treatment.
From the first dose administration to the end of the treatment period (Week 261).
Normalization rate of improvement in alanine aminotransferase (ALT) levels after treatment.
From the first dose administration to the end of the treatment period (Week 261).
Normalization rate of improvement in aspartate aminotransferase (AST) levels after treatment.
From the first dose administration to the end of the treatment period (Week 261).
Magnitude of improvement in aspartate aminotransferase (AST) levels after treatment.
From the first dose administration to the end of the treatment period (Week 261).
עוזר השתתפות
קריטריוני זכאות

גילאים מוערכים למחקר
מבוגר, גיל שלישי
גיל מינימלי למחקר
18 Years
מגדרים מוערכים למחקר
הכל

  • Age 18 to 65 years (inclusive of 18 and 65 years old at the time of signing the informed consent form), male or female;

  • Documented history of chronic hepatitis B and/or positive for hepatitis B surface antigen (HBsAg) for ≥6 months;

  • Treatment-naïve or treatment-experienced patients with chronic hepatitis B, defined as follows:

    1. Treatment-naïve patients must meet all of the following criteria:

      • No prior systemic antiviral therapy (e.g., interferon and/or nucleos(t)ide analogues) before randomization;
      • Positive for HBV DNA;
      • Liver stiffness measurement (LSM) by transient elastography ≥12.4 kPa for treatment-naïve patients with ALT >2 × ULN; or LSM ≥10.6 kPa for treatment-naïve patients with ALT ≤2 × ULN. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver biopsy evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥3.

    2. Treatment-experienced patients must meet all of the following criteria:

      • A history of ≥6 months of continuous nucleos(t)ide analogue therapy for hepatitis B up to randomization, currently receiving monotherapy with a nucleos(t)ide analogue \[e.g., Tenofovir Alafenamide Fumarate (TAF), Tenofovir Disoproxil Fumarate (TDF), or Entecavir (ETV)\];
      • HBV DNA positive or negative is acceptable;
      • Liver stiffness measurement (LSM) by transient elastography >9.0 kPa. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver biopsy evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥3.

  • ALT <8 × ULN;

  • No use within 3 months prior to randomization of the following Chinese patent medicines that may have antifibrotic effects: Fuzhenghuayu Capsule (Tablet), Anluohuaxian Pill, Compound Biejia Ruangan Tablet, etc.;

  • Subjects (or their sexual partners) have no pregnancy plan during the trial and for 6 months after trial completion, voluntarily agree to use effective physical contraceptive methods, and have no plan to donate sperm or eggs;

  • Subjects have fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial prior to participation, voluntarily agree to take part in this clinical trial, are able to communicate well with the investigators, agree to comply with all study requirements, and have provided written informed consent.

  • Total bilirubin (TBil) >3 × ULN, or 3 × ULN < ALT <8 × ULN with TBil >2 × ULN;
  • Platelet count (PLT) ≤50 × 10⁹/L;
  • Prothrombin activity (PTA) <50% or International Normalized Ratio (INR) >1.5;
  • Imaging findings suggestive of a space-occupying lesion in the liver indicative of tumor, or alpha-fetoprotein (AFP) >100 μg/L even in the absence of specific signs of hepatocellular carcinoma;
  • Patients with decompensated liver cirrhosis (complications including ascites, esophageal and/or gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy) or with hepatic malignancy;
  • Patients with chronic hepatitis C or non-viral chronic hepatitis (alcoholic, drug-induced, etc., excluding metabolic dysfunction-associated steatotic liver disease (MASLD));
  • History of alcohol abuse or inability to abstain from alcohol recently \[Note: Alcohol abuse is defined as: ① daily ethanol consumption ≥40 g for males or ≥20 g for females for 5 consecutive years; OR ② history of heavy alcohol consumption (\>80 g of ethanol per day) within the past 2 weeks. Ethanol (g) = volume of alcoholic beverage consumed (mL) × alcohol by volume (%) × 0.8\];
  • Patients with severe concurrent cardiovascular, pulmonary, renal, endocrine, neurological, or hematological diseases, or psychiatric disorders;
  • Pregnant and/or lactating women;
  • Participation in any other drug clinical trial within the past 3 months;
  • Any condition that, in the investigator's judgment, may affect the subject's ability to provide informed consent or comply with the trial protocol, or participation that may affect the trial results or the subject's own safety.
Beijing Continent Pharmaceutical Co, Ltd. logoג'ייר תרפיוטיקס
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine logoShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
איש קשר מרכזי למחקר
איש קשר: Ling Zhang, +86-13501209210, [email protected]
1 מיקומי המחקר ב-1 מדינות
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Lungen Lu, Dr, איש קשר